Evidence method
Level · gp.fundamentals.capex_revenue_ratio
7.56% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Jun 30, 2023
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-23-037234General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-48.15% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
12.06% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
38.75% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
63.39% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-97.74% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
65.89% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
35.45% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 7.77%
- Current
- 7.56%
- Delta
- -0.21%
- Previous
- -157.12%
- Current
- -48.15%
- Delta
- 108.98%
- Previous
- -2.52%
- Current
- 12.06%
- Delta
- 14.58%
- Previous
- 52.79%
- Current
- 38.75%
- Delta
- -14.04%
- Previous
- 50.38%
- Current
- 63.39%
- Delta
- 13.02%
- Previous
- -151.92%
- Current
- -97.74%
- Delta
- 54.18%
- Previous
- 86.60%
- Current
- 65.89%
- Delta
- -20.71%
- Previous
- 38.97%
- Current
- 35.45%
- Delta
- -3.52%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT CAPEX_INTENSITY_DECREASED →Transitioned To · ADPT CASH_GENERATION_INCREASED →Transitioned To · ADPT GROWTH_INCREASED →Transitioned To · ADPT INVENTORY_PRESSURE_DECREASED →Transitioned To · ADPT MARGIN_INCREASED →Transitioned To · ADPT PROFITABILITY_INCREASED →Transitioned To · ADPT R_AND_D_INTENSITY_DECREASED →Transitioned To · ADPT SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.